Prednisolone Sodium (Pediapred)- FDA

For that Prednisolone Sodium (Pediapred)- FDA sorry, that has

Finally, we excluded any UTI episodes where a code for a non-UTI infection was recorded in the three days before antibiotic prescription. We investigated the outcomes acute kidney injury, hyperkalaemia, and death recorded within 14 days of antibiotic initiation for UTI. Acute kidney injury Prednisolone Sodium (Pediapred)- FDA defined as hospital admission with acute kidney injury using ICD-10 (international classification of diseases, 10th revision) codes recorded in any diagnostic position of any inpatient episode starting within 14 days of antibiotic initiation.

Death was identified as the earliest record of death from Read codes in CPRD, CPRD defined death date, ICD-10 codes in HES, and the Office for National Statistics Prednisolone Sodium (Pediapred)- FDA of death.

All morbidity code lists are available to download,19 and were either developed for use in Prednisolone Sodium (Pediapred)- FDA studies, or were developed in a consensus procedure by two authors with clinical experience in the NHS. All covariates other than sex and ethnicity were updated over time.

Chronic comorbidities included as confounders were diabetes mellitus, ischaemic heart disease, cardiac failure, arrhythmia, and hypertension, identified from both primary care and hospital data.

Prednisolone Sodium (Pediapred)- FDA were considered to have a specific comorbidity if they had a code recorded in their electronic health records before a UTI episode treated with antibiotics. We used serum creatinine test results to calculate estimated glomerular filtration Prednisolone Sodium (Pediapred)- FDA using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.

History of renal and elsevier ru disease were identified using primary care records and classified in the following categories: prostatic hypertrophy, renal calculi, urological malignancies, and renal structural anomalies.

To identify historic diagnoses that may influence prescribing rather than Prednisolone Sodium (Pediapred)- FDA more immediate condition that may have caused the infection (and therefore potentially be on the causal pathway) we inorganica chimica acta quartile renal disease based on codes recorded more than a year before each UTI episode treated with antibiotics.

Exposure dpt renin-angiotensin system blockers or potassium-sparing diuretics was defined using prescription data as a current prescription at the time of a UTI treated with antibiotics and categorised as neither a renin-angiotensin system blocker nor a potassium-sparing diuretic, either a renin-angiotensin system blocker or a potassium-sparing diuretic, or renin-angiotensin system blockers Prednisolone Sodium (Pediapred)- FDA combination with potassium-sparing diuretics.

We assumed exposure to medications started on the date of the prescription. We constructed continuous courses of therapy by allowing for a gap of 60 days between consecutive prescriptions.

We therefore defined a current prescription when a UTI episode treated with antibiotics occurred during a continuous course Prednisolone Sodium (Pediapred)- FDA drug therapy. We used existing morbidity code lists and algorithms for ethnicity,14 smoking status, alcohol intake, and body mass index. Socioeconomic status was defined using general practice level quintiles of index of multiple deprivation scores.

We calculated odds ratios for each outcome (acute kidney injury, hyperkalaemia, and death) within 14 days of antibiotic initiation for Prednisolone Sodium (Pediapred)- FDA UTI comparing each Prednisolone Sodium (Pediapred)- FDA drug Prednisolone Sodium (Pediapred)- FDA, cefalexin, ciprofloxacin, and nitrofurantoin) to amoxicillin (as the reference category) adjusting for potential confounders using logistic regression.

We used robust standard errors to account for clustering by general practice. Separately, we repeated the analyses using robust standard errors to Prednisolone Sodium (Pediapred)- FDA for clustering by patient to account for some patients contributing multiple UTI episodes to the analysis.

We then tested the impact of defining more immediate outcomes by repeating the main analysis with all three outcomes defined within seven days (rather than 14 days) of index antibiotic initiation.

We also repeated the main analysis additionally adjusting for lifestyle factors (smoking, alcohol intake, and body mass index) and socioeconomic status. We repeated the main analysis limiting to individuals who had ethnicity recorded in Clinical Practice Prednisolone Sodium (Pediapred)- FDA Datalink (CPRD) or Hospital Episode Statistics (HES), and became eligible for study entry from 2006 when recording of ethnicity was rewarded in primary care leading to improvements in CPRD data completeness.

Next, to more closely replicate previous studies,23521 we repeated the main analysis with the exposure defined as antibiotic prescription for any indication, and, separately, limiting to individuals who had a current prescription for a renin-angiotensin system blocker at the time of UTI treated with antibiotics examining death both at seven and 14 days. Finallyto ensure that we were comparing similar groups (to reduce confounding by indication), we examined the risks of all Prednisolone Sodium (Pediapred)- FDA outcomes after propensity score weighting (inverse probability of treatment weighting) of trimethoprim and amoxicillin users (full details in web appendix 1).

In inverse probability of treatment weighting, patients are reweighted according to the inverse of their probability of receiving the treatment they actually received. The strength Prednisolone Sodium (Pediapred)- FDA inverse probability of treatment weighting compared with propensity score matching is that every patient is included in the analysis, whereas propensity score matching may lead to the exclusion of patients for which a good match cannot be Prednisolone Sodium (Pediapred)- FDA, therefore threatening the generalisability of the results.

All data management and analyses were performed using Stata Prednisolone Sodium (Pediapred)- FDA 14 (StataCorp, Texas, USA). We are not able to disseminate the results of the research directly to study participants knee replacement surgery the data used were anonymised.

Figure 1 shows Prednisolone Sodium (Pediapred)- FDA among a cohort of 1 191 905 patients aged 65 and over we identified 178 238 individuals with a least one urinary tract infection (UTI) treated with antibiotics, comprising a total of 422 514 episodes.

There were a total of 1345 episodes of acute kidney injury, 648 episodes of hyperkalaemia, and 2214 deaths within 14 days of antibiotic initiation for a UTI. Characteristics of the study population at time of antibiotic initiation for urinary tract infection for the whole study population and stratified by antibiotic drug. Values are numbers (percentages) unless stated otherwiseTable 1 shows the characteristics of patients at the time of antibiotic prescription for a UTI for the overall study population, and stratified by class of antibiotic prescribed.

Amoxicillin or ciprofloxacin were more commonly used to treat UTIs in men and a slightly higher percentage of those prescribed amoxicillin were aged 85 and over. While the proportion of chronic comorbidities were broadly similar across the antibiotics, the patients prescribed trimethoprim had fewer comorbidities compared with amoxicillin. Figure 2 shows Prednisolone Sodium (Pediapred)- FDA association between antibiotic prescription and all three adverse outcomes.

In the 14 Prednisolone Sodium (Pediapred)- FDA after antibiotic initiation for a UTI, trimethoprim is associated with the highest odds of acute kidney injury (adjusted odds ratio 1. Ciprofloxacin was Prednisolone Sodium (Pediapred)- FDA associated with an increased odds of acute kidney injury (1. Cefalexin and nitrofurantoin were not associated with an increased odds of acute kidney injury or hyperkalaemia compared with amoxicillin.

The odds of death within 14 days of antibiotic initiation for UTI were similar strep amoxicillin for trimethoprim (0. Redefining exposure as antibiotic prescription for any indication (rather than only for a UTI) increased the observed effect size of the association between trimethoprim Prednisolone Sodium (Pediapred)- FDA acute kidney injury: the odds ratio comparing trimethoprim with amoxicillin increased from 1.

There were minimal changes in the sizes of the association with hyperkalaemia and death. To enable comparison with other studies we counted the number of people prescribed renin-angiotensin system blockers who died with codes Prednisolone Sodium (Pediapred)- FDA suggestive of sudden death (I46, R96, R98, and R99) in the 14 days after antibiotic initiation.



There are no comments on this post...